FDA Accepts Supplement Application for WINREVAIR (Sotatercept-CSRK) by Merck
The FDA has accepted the supplemental biologics license application (BLA) for WINREVAIR (sotatercept-CSRK) submitted by Merck Sharp Dohme.
Asset / Drug
Drug and asset intelligence for WINREVAIR with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.